GlassScriptPhysician profile
Jason D Taffet
NPI 1871156141
$2,008.82
in general payments reported to CMS, 2019-2025
24 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $647 · 2024: $495 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.05 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $224.83 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $192.15 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.17 | 2022-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $164.37 | 2022-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $161.17 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $139.68 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $124.32 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $117.08 | 2022-2025 | |
| Amgen INC. | $113.96 | 2023-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $96.09 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.04 | 2023-2025 | |
| Abbott Laboratories | $85.69 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $64.94 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Nalu Medical, INC. | $43.86 | 2025 | Nalu Neurostimulation System |
| Alexion Pharmaceuticals, INC. | $32.18 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $28.24 | 2025 | Contrave, Onzetra Xsail |
| Mylan Specialty L.P. | $23.23 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $22.08 | 2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $20.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2025 | Trintellix |
| Sanofi Pasteur INC. | $18.59 | 2023 | |
| Inspire Medical Systems, INC. | $18.00 | 2023 | Inspire |
| Viatris Specialty LLC | $17.06 | 2025 | Yupelri |
| Medtronic, INC. | $13.63 | 2025 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Taffet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.